Drugs / GenSci136
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07366866 | Mar 2026 → Feb 2027 expected | autoimmune disease | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci: Two Innovations Granted IND Clearance by FDA genscigroup.com ↗
Recently, GenSci145 and GenSci136 have both secured FDA clinical trial approvals, developed respectively for PIK3CA -mutated locally advanced or metastatic solid tumors and myasthenia gravis (MG). |
| 2026-02-14 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci136, an APRIL/BAFF Dual Antagonist, Granted Clinical Trial Approval for IgAN genscigroup.com ↗
Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci") recently announced that the National Medical Products Administration (NMPA) has approved an IND application of GenSci136 for Injection, a dual APRIL/BAFF antagonist in development for the treatment of Immunoglobulin A nephropathy (IgAN). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci: Two Innovations Granted IND Clearance by FDA genscigroup.com ↗ |
| 2026-02-14 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci136, an APRIL/BAFF Dual Antagonist, Granted Clinical Trial Approval for IgAN genscigroup.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07366866 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC)” NCT07366866 ↗ |